Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC

NCT01004250 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01004250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01004250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2009
Completion date
December 31, 2013
Enrollment
109 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer